Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers (HCPs), today announced the publication of a study in
B. Riley Securities analyst Marc Wiesenberger downgrades Semler Scientific (NASDAQ:SMLR) from Buy to Neutral and lowers the price target from $60 to $45.